- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xilio Therapeutics Inc (XLO)
9.040
+0.020(+0.22%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.950
9.160
52 wk Range
6.465
12.739
Xilio Therapeutics (XLO) Income Statement & Profits
Assess the Xilio Therapeutics income statement (earnings report) to see how the company performs across operating and non-operating activities, including revenue, expenses and net income. Review XLO diluted EPS and profitability over the last four annual or quarterly periods.
Investors who need greater depth or who want to customise how data is presented to fit their own investment styles are able to do so via their very own InvestingPro account.
Investors who need greater depth or who want to customise how data is presented to fit their own investment styles are able to do so via their very own InvestingPro account.
| Period Ending: | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | 2025 31/12 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | - | - | - | 6.34 | 43.77 | |||||||||
Total Revenues Growth | aa.aa | aa.aa | - | - | - | - | +589.88% | |||||||||
Cost Of Revenues | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Gross Profit | aa.aa | aa.aa | - | - | - | 6.34 | 43.77 | |||||||||
Gross Profit Growth | aa.aa | aa.aa | - | - | - | - | +589.88% | |||||||||
Gross Profit Margin % | aa.aa | aa.aa | - | - | - | 100% | 100% | |||||||||
Other Operating Expenses, Total | aa.aa | aa.aa | 75.04 | 89.15 | 79.13 | 65.99 | 85.75 | |||||||||
| ||||||||||||||||
Operating Income | aa.aa | aa.aa | -75.04 | -89.15 | -79.13 | -59.65 | -41.98 | |||||||||
Operating Income Growth | aa.aa | aa.aa | -37.54% | -18.8% | +11.24% | +24.63% | +29.61% | |||||||||
EBIT Margin % | aa.aa | aa.aa | - | - | - | -940.18% | -95.92% | |||||||||
Net Interest Expenses | aa.aa | aa.aa | -0.6 | -0.8 | -0.7 | - | - | |||||||||
Net Interest Expenses Growth | aa.aa | aa.aa | 0% | -33.33% | +12.5% | - | - | |||||||||
Interest Expense, Total | aa.aa | aa.aa | -0.6 | -0.8 | -0.7 | - | - | |||||||||
Interest And Investment Income | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Other Non Operating Expenses, Total | aa.aa | aa.aa | -0.16 | 1.73 | 3.43 | 2.34 | 6.95 | |||||||||
EBT, Excl. Unusual Items | aa.aa | aa.aa | -75.8 | -88.22 | -76.4 | -57.3 | -35.04 | |||||||||
Gain (Loss) On Sale Of Assets | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Other Unusual Items, Total | aa.aa | aa.aa | - | - | - | - | - | |||||||||
EBT, Incl. Unusual Items | aa.aa | aa.aa | -75.8 | -88.22 | -76.4 | -58.24 | -35.04 | |||||||||
EBT, Incl. Unusual Items Growth | aa.aa | aa.aa | -37.27% | -16.39% | +13.4% | +23.77% | +39.84% | |||||||||
EBT, Incl. Unusual Items Margin | aa.aa | aa.aa | - | - | - | -918.05% | -80.05% | |||||||||
Income Tax Expense | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Net Income to Company | aa.aa | aa.aa | -75.8 | -88.22 | -76.4 | -58.24 | -35.04 | |||||||||
Minority Interest | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Net Income | aa.aa | aa.aa | -75.8 | -88.22 | -76.4 | -58.24 | -35.04 | |||||||||
Net Income Growth | aa.aa | aa.aa | -37.27% | -16.39% | +13.4% | +23.77% | +39.84% | |||||||||
Net Income Margin % | aa.aa | aa.aa | - | - | - | -918.05% | -80.05% | |||||||||
Preferred Dividend and Other Adjustments | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Net Income to Common Excl. Extra Items | aa.aa | aa.aa | -75.8 | -88.22 | -76.4 | -58.24 | -35.04 | |||||||||
Basic EPS - Continuing Operations | aa.aa | aa.aa | -189.29 | -45.09 | -38.9 | -15.24 | -7.73 | |||||||||
Basic EPS - Continuing Operations Growth | aa.aa | aa.aa | +87.18% | +76.18% | +13.72% | +60.83% | +49.25% | |||||||||
Diluted EPS - Continuing Operations | aa.aa | aa.aa | -189.29 | -45.09 | -38.9 | -15.24 | -7.73 | |||||||||
Diluted EPS - Continuing Operations Growth | aa.aa | aa.aa | +87.18% | +76.18% | +13.72% | +60.83% | +49.25% | |||||||||
Basic Weighted Average Shares Outstanding | aa.aa | aa.aa | 0.4 | 1.96 | 1.96 | 3.82 | 4.53 | |||||||||
Diluted Weighted Average Shares Outstanding | aa.aa | aa.aa | 0.4 | 1.96 | 1.96 | 3.82 | 4.53 | |||||||||
Dividend Per Share | aa.aa | aa.aa | - | - | - | - | - | |||||||||
Dividend Per Share Growth | aa.aa | aa.aa | - | - | - | - | - | |||||||||
EBITDA | aa.aa | aa.aa | -73.55 | -87.3 | -77.23 | -58 | -40.44 | |||||||||
EBITDA Growth | aa.aa | aa.aa | -37.47% | -18.71% | +11.53% | +24.9% | +30.28% | |||||||||
EBITDA Margin % | aa.aa | aa.aa | - | - | - | -914.27% | -92.4% | |||||||||
EBIT | aa.aa | aa.aa | -75.04 | -89.15 | -79.13 | -59.65 | -41.98 | |||||||||
* In Millions of USD (except for per share items)
FAQ
What was Xilio Therapeutics’s revenue at year end?
At the end of the last reported fiscal year, Xilio Therapeutics (XLO) recorded total revenue of 43.766 million USD.
How much revenue did Xilio Therapeutics report in the most recent quarter?
In its most recent quarterly earnings report, Xilio Therapeutics posted revenue of 18.692 million USD.
What was Xilio Therapeutics’s net income for the year?
For the last full fiscal year, Xilio Therapeutics reported net income of -35.036 million USD.
How much net income did Xilio Therapeutics post in the last quarter?
In the most recent quarter, Xilio Therapeutics (XLO) posted net income of -6.373 million USD.
What was Xilio Therapeutics’s gross profit for the year?
Gross profit for the latest fiscal year was reported at 43.766 million USD.
How much gross profit did Xilio Therapeutics generate last quarter?
Xilio Therapeutics recorded gross profit of 4.133 million USD in its latest quarterly report.
What was Xilio Therapeutics’s annual operating income?
For the latest full fiscal year, Xilio Therapeutics (XLO) reported operating income of -41.982 million USD.
What was Xilio Therapeutics’s operating income last quarter?
Quarterly operating income was -3.491 million USD.
What was Xilio Therapeutics’s quarterly EBITDA?
In the latest quarter, XLO's EBITDA was reported at -3.160 million USD.
What was the quarter-over-quarter change in EBITDA for Xilio Therapeutics?
XLO's EBITDA changed by 77.048% compared to the last quarter.
What is Xilio Therapeutics’s most recent gross profit margin?
The latest reported gross profit margin for Xilio Therapeutics (XLO) is 22.111% million USD.
What is Xilio Therapeutics’s most recent net income margin?
Net income margin based on recent financials is -34.095% million USD.
What is Xilio Therapeutics’s most recent EBIT margin?
Xilio Therapeutics reported an EBIT margin of -18.676% million USD based on current figures.
How did Xilio Therapeutics’s revenue change compared to the previous quarter?
Revenue changed by 47.786% compared to the prior quarter.
What was the quarter-over-quarter change in gross profit for Xilio Therapeutics?
In the latest quarter, Xilio Therapeutics's gross profit changed by 157.531%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.